JP2016508995A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508995A5
JP2016508995A5 JP2015554038A JP2015554038A JP2016508995A5 JP 2016508995 A5 JP2016508995 A5 JP 2016508995A5 JP 2015554038 A JP2015554038 A JP 2015554038A JP 2015554038 A JP2015554038 A JP 2015554038A JP 2016508995 A5 JP2016508995 A5 JP 2016508995A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
formula
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015554038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/071205 external-priority patent/WO2014114248A1/en
Publication of JP2016508995A publication Critical patent/JP2016508995A/ja
Publication of JP2016508995A5 publication Critical patent/JP2016508995A5/ja
Pending legal-status Critical Current

Links

JP2015554038A 2013-01-25 2014-01-23 化合物 Pending JP2016508995A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013070970 2013-01-25
CNPCT/CN2013/070970 2013-01-25
PCT/CN2014/071205 WO2014114248A1 (en) 2013-01-25 2014-01-23 Compounds

Publications (2)

Publication Number Publication Date
JP2016508995A JP2016508995A (ja) 2016-03-24
JP2016508995A5 true JP2016508995A5 (OSRAM) 2016-12-28

Family

ID=51226938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554038A Pending JP2016508995A (ja) 2013-01-25 2014-01-23 化合物

Country Status (10)

Country Link
US (1) US9296755B2 (OSRAM)
EP (1) EP2948457A4 (OSRAM)
JP (1) JP2016508995A (OSRAM)
KR (1) KR20150111356A (OSRAM)
CN (1) CN105008365B (OSRAM)
AU (1) AU2014210259B2 (OSRAM)
BR (1) BR112015017768A2 (OSRAM)
CA (1) CA2899124A1 (OSRAM)
RU (1) RU2015135806A (OSRAM)
WO (1) WO2014114248A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
JP7564872B2 (ja) 2019-11-09 2024-10-09 シャンハイ エスアイエムアール バイオテクノロジー カンパニー リミテッド 三環式ジヒドロイミダゾピリミドン誘導体、その調製方法、その医薬組成物及び使用
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
PL320937A1 (en) 1994-12-22 1997-11-10 Smithkline Beecham Plc Substituted azetidin-2-ones for treating arterial atheromatosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
SK178497A3 (en) 1995-07-01 1998-07-08 Smithkline Beecham Plc Azetidinone derivatives, method for producing the same, pharmaceutical composition containing same and their use
WO1997012963A2 (en) 1995-09-29 1997-04-10 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
PL329530A1 (en) 1996-04-26 1999-03-29 Smithkline Beecham Plc Derivatives of azetidinone for use in treatment of arterial atheromatosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
ES2203988T3 (es) 1997-11-06 2004-04-16 Smithkline Beecham Plc Compuestos de pirimidinona y composiciones farmaceuticas que los contienen.
EP1105377B1 (en) 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
US6953803B1 (en) 1999-05-01 2005-10-11 Smithkline Beecham P.L.C. Pyrimidine compounds
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
KR100781425B1 (ko) 2000-02-16 2007-12-03 스미스클라인비이참피이엘시이 Ldl-pla2 억제제로서 피리미딘-4-온 유도체
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20040077635A1 (en) 2002-10-02 2004-04-22 Qiao Jennifer X. Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor Xa inhibitors
NZ539211A (en) 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
WO2008048867A2 (en) 2006-10-13 2008-04-24 Glaxo Group Limited Bicyclic heteroaromatic compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
CA2687079A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EP2521724B1 (en) 2009-12-11 2016-11-23 Nono Inc. Agents and methods for treating ischemic and other diseases
CA2820408C (en) * 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
UY34216A (es) * 2011-07-27 2013-02-28 Glaxo Group Ltd Nuevos compuestos que inhiben la actividad de la Lp-PLA2

Similar Documents

Publication Publication Date Title
JP2013537203A5 (OSRAM)
JP2017504635A5 (OSRAM)
JP2019524883A5 (OSRAM)
JP2014511891A5 (OSRAM)
JP2016531126A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2017071634A5 (OSRAM)
RU2016134751A (ru) Соединения
JP2016514159A5 (OSRAM)
JP2014521688A5 (OSRAM)
JP2019518766A5 (OSRAM)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2016530259A5 (OSRAM)
JP2015509535A5 (OSRAM)
JP2017509586A5 (OSRAM)
JP2016518328A5 (OSRAM)
JP2015508103A5 (OSRAM)
JP2014501766A5 (OSRAM)
JP2013545785A5 (OSRAM)
JP2016506961A5 (OSRAM)
JP2013542261A5 (OSRAM)
JP2015522650A5 (OSRAM)
JP2017514910A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2016512547A5 (OSRAM)